Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2016

Jul 19, 2016

33651_dirs_2016-07-18_844f8a67-a3be-4112-932f-c0dcc288af51.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2016-07-14

Reporting Person: Hillsberg Sanford (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-07-14 Stock Option (right to buy) $0.41 A 100000 Acquired 2026-07-14 Common Stock (100000) Direct

Footnotes

F1: Granted pursuant to the Issuer's 2016 Incentive Plan.

F2: This stock option will vest and become exercisable in equal, quarterly installments over one year, beginning three months from July 14, 2016, such that the option will be fully exercisable as of July 14, 2017.